PMID- 9028934
OWN - NLM
STAT- MEDLINE
DCOM- 19970317
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 89
IP  - 4
DP  - 1997 Feb 15
TI  - Use of leukemic dendritic cells for the generation of antileukemic cellular 
      cytotoxicity against Philadelphia chromosome-positive chronic myelogenous 
      leukemia.
PG  - 1133-42
AB  - The success of adoptive immunotherapy for the treatment of leukemia depends on 
      the generation of T cells that can specifically react with malignant cells. 
      Dendritic cells (DCs) are important antigen-presenting cells in the development 
      of antileukemic T-cell responses. In this study, we generated DCs from peripheral 
      blood cells of patients with chronic myelogenous leukemia (CML). CML cells 
      incubated concurrently with granulocyte-macrophage colony-stimulating factor, 
      interleukin-4, and tumor necrosis factor-alpha in vitro developed morphologic and 
      phenotypic characteristics of DCs. Fluorescence in situ hybridization showed the 
      presence of t(9;22) in the nuclei of these cells, indicating that they were 
      leukemic in origin. These cells were potent stimulators of lymphocyte 
      proliferation in specific in vitro assays for DC function. Autologous T cells 
      stimulated with in vitro-generated, leukemic DCs displayed vigorous cytotoxic 
      activity against CML cells but low reactivity to major histocompatability 
      complex-matched normal bone marrow cells. Cytotoxic activity against CML targets 
      was fourfold to sixfold higher using DC-stimulated autologous T cells than with 
      autologous T cells expanded by culture with interleukin-2 alone. DC-stimulated T 
      cells also inhibited growth of CML clonogenic precursors in colony-forming assays 
      in vitro. These results suggest that cytokine-driven in vitro differentiation of 
      CML cells results in generation of DCs with potent T-cell stimulatory function. 
      In vitro-generated DCs can be effectively used as antigen-presenting cells for 
      the ex vivo expansion of antileukemic T cells.
FAU - Choudhury, A
AU  - Choudhury A
AD  - Department of Hematology and Laboratory Medicine, University of Texas M.D. 
      Anderson Cancer Center, Houston 77030, USA.
FAU - Gajewski, J L
AU  - Gajewski JL
FAU - Liang, J C
AU  - Liang JC
FAU - Popat, U
AU  - Popat U
FAU - Claxton, D F
AU  - Claxton DF
FAU - Kliche, K O
AU  - Kliche KO
FAU - Andreeff, M
AU  - Andreeff M
FAU - Champlin, R E
AU  - Champlin RE
LA  - eng
GR  - CA49639/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Cell Differentiation/drug effects
MH  - Coculture Techniques
MH  - Cytokines/*pharmacology
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*immunology/pathology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-2/pharmacology
MH  - Interleukin-4/pharmacology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*immunology
MH  - Leukemia, Myeloid, Chronic-Phase/*immunology
MH  - Lymphocyte Activation
MH  - Neoplastic Stem Cells/*immunology/pathology
MH  - T-Lymphocyte Subsets/drug effects/immunology
MH  - T-Lymphocytes, Cytotoxic/drug effects/*immunology
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Tumor Stem Cell Assay
EDAT- 1997/02/15 00:00
MHDA- 1997/02/15 00:01
CRDT- 1997/02/15 00:00
PHST- 1997/02/15 00:00 [pubmed]
PHST- 1997/02/15 00:01 [medline]
PHST- 1997/02/15 00:00 [entrez]
AID - S0006-4971(20)58835-6 [pii]
PST - ppublish
SO  - Blood. 1997 Feb 15;89(4):1133-42.